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In asthmatic airways, adenosine is a potent bronchoconstrictor with either pro- or anti-inflam-
matory effects depending on receptor interactions. While aspirin has been suggested to
mediate adenosine action, the roles of adenosine and its receptors in aspirin-intolerant asthma
(AIA) are not well-defined. Therefore, we evaluated associations between genetic polymor-
phisms of adenosine deaminase and the four adenosine receptors (A1, A2A, A2B, and A3) with
the AIA phenotype. The genes for adenosine deaminase (ADA) and the four adenosine recep-
tors (ADORA1, ADORA2A, ADORA2B, and ADORA3) were screened by direct sequencing, and
13 single nucleotide polymorphisms (SNPs) were selected among 23 polymorphisms. Using
multivariate logistic regression analysis, we compared the frequencies of SNP genotypes and
haplotypes among 136 patients with AIA, 181 patients with aspirin-tolerant asthma (ATA),
and 183 normal individuals. We found significant differences between normal and patients with
AIA in the ADORA1 SNP genotype frequencies for 1405C> T (PZ 0.001) and A102A (PZ 0.013).
No other significant associations were detected for the other SNPs. In the haplotype analysis,
ht[CeTeG] (PZ 0.003) and ht[AeCeG] (PZ 0.032) in ADORA1 and ht[AeT] in ADORA2inase; AHR, airway hyperresponsiveness; AIA, aspirin-intolerant asthma; AMP, adenosine mono-
a; COX, cyclooxygenase FEV1, forced expiratory volume in 1 s; GPR, G protein-coupled receptors; LD,
roidal anti-inflammatory drug; SNP, single nucleotide polymorphism; UTR, untranslated regions.
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Adenosine deaminase and adenosine receptor polymorphisms 357(PZ 0.013) were significantly associated with AIA. Genetic polymorphisms of adenosine recep-
tors A1 and A2A were associated with AIA, suggesting that adenosine might play a crucial role in
the development of AIA through interactions with the A1 and A2A receptors.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Aspirin-intolerant asthma (AIA) is a unique clinical
syndrome found in 10e20% of adult patients with asthma1
and characterized by acute bronchoconstriction following
the administration of aspirin and/or nonsteroidal anti-
inflammatory drugs (NSAIDs). Suggested molecular mecha-
nisms for AIA are increased production and/or expression of
cysteinyl leukotrienes and their receptors, dysregulation of
cyclooxygenase and prostaglandins, and more severe
eosinophilic inflammation.2 Additionally, genetic poly-
morphisms in these mediators and receptors have exhibited
significant associations with aspirin intolerance in patients
with asthma.3
The purine nucleoside adenosine is endogenous in
human tissues at low concentrations but adenosine accu-
mulates markedly in the extracellular space during tissue
hypoxia and inflammation.4 Adenosine levels are elevated
following exercise,5 challenge with allergens,6 and in
patients with asthma.7 In addition, inhalation of adenosine
induces acute bronchoconstriction in those with asthma,
and this is used to evaluate airway hyperresponsiveness
(AHR).8 The biological activities of adenosine are primarily
mediated through its interactions with the 7-trans-
membrane G protein-coupled receptors (GPRs) A1, A2A, A2B,
and A3, which transduce signals by interaction with G
proteins to modulate intracellular cyclic adenosine mono-
phosphate (AMP) levels.9 Recently, the specific roles of
these receptors have been extensively explored and these
four GPRs are important targets for developing antiasthma
therapies.10 Extracellular adenosine is produced by alkaline
phosphatase from adenosine triphosphate. Adenosine is
catabolized by adenosine deaminase (ADA), and blocking
ADA induces the accumulation of adenosine and severe
pulmonary inflammation.11
The role of adenosine and its receptors in AIA pathogen-
esis is not well clarified. In subjects with asthma, lysinee
aspirin inhalation attenuates the bronchoconstrictor
response induced by AMP inhalation, and this protective
effect is linked to cyclooxygenase (COX) inhibition and
reduced production of contractile prostaglandins and
thromboxanes.12 While aspirin and NSAIDs reduce inflam-
mation through inhibition of COX and prostaglandin
synthesis, they also produce anti-inflammatory effects that
aremediated through adenosinemetabolism and adenosine-
receptor interactions.13e15 In addition, the elimination of
extracellular adenosine from inflammatory exudates using
ADA reverses the anti-inflammatory effects of aspirin.13
Moreover, the A2A adenosine receptor is reported to have
a protective role in aspirin-induced gastric mucosal inflam-
mation.16 Taken together, these findings suggest that aden-
osine-mediated mechanisms are involved in the
development of AIA. Although a few studies have reported on
genetic associations of ADA with asthma and IgE-mediated
responses,17e19 no trial has examined the associationsbetween adenosine-related genes and aspirin intolerance in
asthma. Therefore, in the present study, we evaluated
whether genetic polymorphisms in ADA and the four known
adenosine receptors (A1, A2A, A2B, andA3) are associatedwith
the development of AIA in a Korean population.
Materials and methods
Subjects
We enrolled 136 patients with AIA and 181 patients with
aspirin-tolerant asthma (ATA) from five general hospitals
(Ajou University Hospital, Seoul National University
Hospital, Dankook University Hospital, Hanyang University
Hospital, and Eulji University Hospital) in Korea. As normal
controls, 183 healthy subjects without respiratory symp-
toms and with normal lung function were recruited. This
study was approved by the institutional review board of
each hospital and informed consent was obtained from all
subjects. Asthma was defined as the presence of typical
asthmatic symptoms and the demonstration of AHR to
methacholine (PC20< 16 mg/ml) and/or reversible airway
obstruction as evidenced by a bronchodilator test involving
inhalation of a short-acting b2 agonist [>15% of predicted
value and a 200 ml increase in forced expiratory volume in
1 s (FEV1)].
20 Subjects with asthma were diagnosed as AIA if
they exhibited a positive response to the lysineeaspirin
bronchoprovocation test according to a previously
described protocol.21,22 The smoking status, rhinitis symp-
toms, onset time of asthmatic symptoms, and previous
history of aspirin intolerance were observed for all patients
with asthma. Those exhibiting a negative response to the
aspirin challenge test and no history of aspirin and/or NSAID
intolerance were classified as having ATA. Normal controls
were recruited from volunteers lacking asthmatic symp-
toms, a history of aspirin intolerance, AHR to methacho-
line, and a positive response to the aspirin challenge test.
Atopy was defined as one or more positive responses to
locally common aeroallergens in a skin prick test and/or
a positive specific IgE response to house dust mite aller-
gens. Spirometry was performed to measure basal FEV1 and
forced vital capacity. PNS X-ray and rhinoscopic examina-
tions were carried out to evaluate rhinosinusitis and the
presence of nasal polyps. The serum levels of total IgE were
measured by the CAP system (Pharmacia, Uppsala, Swe-
den). The clinical characteristics of the three study groups
are summarized in Table 1.
Identification of SNPs
Genomic DNA samples were isolated from the peripheral
blood of 24 healthy subjects using the QIAamp DNA blood
kit according to the manufacturer’s instructions (Qiagen,
Hilden, Germany). For SNP identification, up to 2 kb of the
Table 1 Clinical characteristics of the subjects.
Characteristic AIA (nZ 136) ATA (nZ 181) NC (nZ 183)
Male* (%) 49 (36.0) 81 (44.8) 88 (48.1)
Age (years)y 44.1 12.7 40.0 14.1 38.6 14.3
Asthma duration (years) 6.6 6.1 6.4 5.9 NA
Baseline FEV1 (% of predicted value)
z 83.3 23.2 89.2 15.4 94.4 8.2
PC20 (mg/ml of methacholine) 4.67 13.0 6.7 10.3 NA
Rhinosinusitis (%) 81/101 (80.2) 133/177 (75.1) NA
Nasal polypx (%) 47/91 (51.6) 10/177 (5.6) NA
Total serum IgE (IU/ml) 309.3 415.4 362.5 672.7 NA
Atopyk (%) 66/104 (63.5) 120/177 (67.8) 56/180 (31.1)
Mean SD.
AIA, aspirin-intolerant asthma;ATA, aspirin-tolerant asthma;NC, normal control; NA, not applicable; FEV1, forcedexpiratory volume in 1 s.
*PZ 0.031 for AIA versus NC by chi-square test;. yPZ 0.007 for AIA versus ATA, P< 0.001 for AIA versus NC by Student’s t-test;. zPZ 0.017
for AIA versus ATA, PZ 0.024 for ATA versus NC, P < 0.001 for AIA versus NC by Student’s t-test;. x P < 0.001 for AIA patients versus ATA
patients by chi-square test; kP < 0.001 for AIA versus NC, P < 0.001 for ATA versus NC by chi-square test.
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promoter, and all the exons, including the 30-untranslated
regions (UTRs) of five candidate genes (ADA, NM_000022;
ADORA1, NM_000674; ADORA2A, NM_000675; ADORA2B,
NM_000676; ADORA3, NM_000677; Supplementary Fig. 1)
were sequenced in both directions based on the reference
sequences using the Big Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, CA,
USA). From the sequences, we screened informative SNPs
with minor allele frequencies of >0.05.
Genotyping and haplotype inference
For selection of tagging SNPs among the informative SNPs,
we gave priority to non-synonymous coding SNPs and SNPs
that tagged most of the remaining variants after determi-
nation of the linkage disequilibrium (LD) patterns (Supple-
mentary Fig. 1). The selected SNPs were genotyped in the
study subjects using the high-throughput single base-pair
extension method (SNP-IT assay) with the SNPstream25K
system, which was customized to genotype automatically
the DNA samples in 384-well plates and to generate
a colorimetric readout (Orchid Biosciences, Princeton, NJ,
USA), as described previously.23 After examining Lewontin’s
D0 (jD0j) and the LD coefficient r2 between all pairs of
biallelic loci, haplotypes and their frequencies were esti-
mated using Haploview version 3.32 (http://www.broad.
mit.edu/mpg/haploview/).
Statistical analysis
Differences in phenotypes among the three subject groups
(patients with AIA, patients with ATA, and normal controls)
were determined using Student’s t-test or chi-square test.
HardyeWeinberg equilibrium was assessed using the chi-
square test. Genotype frequencies of SNPs and haplotype
frequencies were compared among the groups by multi-
variate logistic regression analysis using age and sex as
covariates. We used dominant and recessive analysis
models for comparisons of the genotype frequencies. All of
the statistical analyses were performed using SAS (version9.13; SAS Institute, Cary, NC, USA) and P values <0.05 were
regarded as statistically significant.Results
Selection of SNPs in ADA, ADORA1, ADORA2A,
ADORA2B, and ADORA3
Through direct sequencing of the ADA, ADORA1, ADORA2A,
ADORA2B, and ADORA3 genes and evaluation of minor allele
frequencies and LD between SNPs, we selected 13 tagging
SNPs in four genes for genotyping as followings: 1130A>T
and V178V in ADA; 38242C> T, A102A, 1278C> A,
1405C> T, and 1627G> T in ADORA1; 1751A> C and
Y361Y in ADORA2A; 2288A>G, 1050G> T, 564C> T,
and A299A in ADORA3 (Table 2). In ADORA2B, no SNP with
minor allele frequency >0.05 existed, and thus genotyping
of the study subjects was not carried out (Supplementary
Table 1).
Associations between SNPs and AIA
Genotype frequencies of two SNPs of ADA (1130A>T and
V178V) were not different among subject groups (Table 3).
Of five selected SNPs of ADORA1 (38242C> T, A102A,
1278C> A, 1405C> T, and 1627 G> T), A102A in exon 5 and
1405C> T in the 30-UTR of exon 6 showed significant asso-
ciations with AIA. In A102A, the frequency of the variant
allele (G) containing genotypes (TG and GG) was lower in
patients with AIA than in normal controls (25.4% versus
39.3%, PZ 0.013, ORZ 0.52, 95% CIZ 0.30e0.87), sug-
gesting a protective role of the variant allele in the
development of AIA. The frequency of homozygotes of the
mutant allele (TT) of 1405C> T was higher in patients with
AIA compared to normal controls (18.8% versus 6.6%,
PZ 0.001, ORZ 3.22, 95% CIZ 1.50e6.92), which implied
that 1405C> T conferred a strong risk for AIA. No significant
association was observed between the other three SNPs of
ADORA1 (38242C> T, 1278C> A, and 1627G> T) and the
AIA phenotype. In two SNPs of ADORA2A (1751A> C and
Table 2 Selected single nucleotide polymorphisms for genotyping.
Gene SNP Reference SNP ID Position Minor allele frequency HWE (P value)
ADA 1130A>T rs11086932 Promoter 0.354 0.733
V178V rs244076 Exon 6 0.083 1
ADORA1 38242C> T rs6664108 Promoter 0.229 1
A102A rs10920568 Exon 5 0.167 1
1278C> A rs6427994 Exon 6 (30-UTR) 0.167 1
1405C> T rs16851030 Exon 6 (30-UTR) 0.375 0.004
1627G> T rs12744240 Exon 6 (30-UTR) 0.125 1
ADORA2A 1751A> C rs5996696 Promoter 0.062 1
Y361Y rs5751876 Exon 2 0.438 1
ADORA3 2288A>G rs2298191 Promoter 0.229 0.452
1050 G> T rs10776727 Promoter 0.396 0.326
564C> T rs1544224 Exon 1 (50-UTR) 0.292 1
A299A rs2229155 Exon 2 0.188 1
HWE, HardyeWeinberg equilibrium.
Adenosine deaminase and adenosine receptor polymorphisms 359Y361Y) and four SNPs of ADORA3 (2288A> G,
1050 G> T, 564C> T, and A299A), genotype frequencies
were not significantly different among the groups.
Association between gene haplotypes with AIA
Based on the LD between the genotyped SNPs, we inferred
the haplotype frequencies for three genes, ADORA1,
ADORA2A, and ADORA3 (Table 4). In the analysis of the
association between haplotypes and AIA, a significant asso-
ciation was found for ADORA1 and ADORA2A. The frequency
of ht2[CeTeG] ofADORA1, which carried themutant Tallele
of 1405C> T, the risk allele inAIAdevelopment,washigher in
the AIA group than in the normal controls (PZ 0.003,
ORZ 3.04, 95% CIZ 1.42e6.50) and the frequency of
ht3[AeCeG] containing theCallele of 1405C> Twas lower in
patients with AIA than in those with ATA (PZ 0.032,
ORZ 0.56, 95% CIZ 0.33e0.95). While no SNP was associ-
ated with AIA in the previous single SNP analysis in the
adenosineA2 gene, ht2[AeT] showeda significant association
with the AIA phenotype with lower frequency in AIA than in
normal controls (PZ 0.013, ORZ 0.33, 95% CIZ 0.13e
0.82). These findings suggest that ht2[AeT] in ADORA2A had
a protective role in the development of AIA.
Functional role of 1405C> T in AIA pathogenesis
We evaluated the functional role of 1405C> T of ADORA1,
which was determined to be a risk allele for AIA by both SNP
and haplotype analyses. During aspirin inhalation bronchial
challenge in patients with AIA, those with the TT genotype
of 1405C> T showed a positive response earlier than those
with other genotypes (PZ 0.009) (Fig. 1).
Discussion
Candidate gene approaches in AIA have been inspired by
the current understanding that increased levels of cysteinyl
leukotrienes act as the key inflammatory mediators in thedevelopment of AIA and the protective prostanoids are
decreased in AIA. As a result, many studies in AIA genetics
have focused on genes related to eicosanoid metabolism
and its receptors, which revealed AIA-associated genetic
polymorphisms such as ALOX5,21 LTC4,24 CYSLTR2,25
TBXA2R,26 and prostanoid receptors.27 In the present study,
we explored possible associations between AIA and poly-
morphisms in adenosine-related genes for the first time and
revealed that SNPs in ADORA1, but not in ADA, ADORA2A,
ADORA2B, and ADORA3, were significantly associated with
AIA. Additionally, the haplotype of ADORA1 and ADORA2A
exhibited significant associations with AIA.
The expression of the A1 adenosine receptor was
elevated in the bronchial epithelium and smooth muscle of
subjects with asthma,28 and this receptor mediated bron-
choconstriction induced by exogenous adenosine.29 Thera-
peutic effects of blocking the A1 receptor were evaluated in
animal models of asthma using antisense oligonucleoside30
and specific antagonists.31 In these experiments, both
agents attenuated adenosine- and allergen-induced bron-
choconstriction without notable anti-inflammatory effect.
In terms of a regulatory role in inflammation, the A1
receptor showed both pro- and anti-inflammatory effects.
Adenosine increased mucus secretion and activated
neutrophils and monocytes via the A1 receptor.
32 In
contrast, the A1 receptor proved to have a protective effect
on lung inflammation in ADA and A1 double-knockout
mice.33 In the present study, the minor allele (T) in
1405C> T in the 30-UTR conferred susceptibility to AIA,
while A102A had a protective effect. Although the func-
tional roles of these variants were not defined, the present
data showed more rapid bronchoconstriction and decreased
FEV1 to aspirin inhalation in patients with TT homozygotes
in 1405C> T compared to those with CC or CT among
patients with AIA. Coupled with the presence of the TT
genotype in ADORA1 with a high risk for AIA, the sensitivity
of patients with AIA having the TT genotype to inhaled
aspirin also implied that genetic variants of the A1 receptor
could have major clinical effects on modifying
bronchoconstriction.
Table 3 Genotype frequencies of single nucleotide polymorphisms in patients with AIA, ATA, and control subjects.
Gene SNP Genotype AIA (nZ 136) ATA (nZ 181) NC (nZ 183) P value
AIA vs. ATA AIA vs. NC ATA vs. NC
ADA 1130A>T AA 61 (54.5) 84 (46.9) 104 (57.1) NS NS NS
AT 41 (36.6) 84 (46.9) 63 (34.6)
TT 10 (8.9) 11 (6.2) 15 (8.2)
V178V AA 87 (75.7) 128 (73.6) 139 (78.5) NS NS NS
AG 26 (22.6) 39 (22.4) 35 (19.8)
GG 2 (1.7) 7 (4.0) 3 (1.7)
ADORA1 38242C> T CC 67 (58.3) 90 (51.4) 87 (49.4) NS NS NS
CT 43 (37.4) 69 (39.4) 80 (45.5)
TT 5 (4.4) 16 (9.1) 9 (5.1)
A102A TT 85 (74.6) 114 (63.7) 111 (60.7) NS 0.013* NS
TG 28 (24.6) 60 (33.5) 68 (37.2)
GG 1 (0.9) 5 (2.8) 4 (2.2)
1278C> A CC 87 (75.0) 114 (63.7) 128 (70.3) NS NS NS
AC 27 (23.3) 59 (33.0) 49 (26.9)
AA 2 (1.7) 6 (3.4) 5 (2.8)
1405C> T CC 51 (43.6) 91 (51.4) 90 (49.7) NS 0.001y NS
CT 44 (37.6) 67 (37.9) 79 (43.7)
TT 22 (18.8) 19 (10.7) 12 (6.6)
1627 G> T GG 89 (77.4) 133 (75.1) 129 (70.5) NS NS NS
GT 25 (21.7) 42 (23.7) 52 (28.4)
TT 1 (0.9) 2 (1.1) 2 (1.1)
ADORA2A 1751A> C AA 76 (66.1) 135 (75.4) 135 (75.8) NS NS NS
AC 38 (33.0) 44 (24.6) 40 (22.5)
CC 1 (0.9) 0 (0.0) 3 (1.7)
Y361Y CC 33 (28.7) 58 (33.1) 48 (26.5) NS NS NS
CT 64 (55.7) 78 (44.6) 94 (51.9)
TT 18 (15.7) 39 (22.3) 39 (21.6)
ADORA3 2288A>G AA 54 (46.2) 74 (41.6) 88 (49.2) NS NS NS
AG 54 (46.2) 84 (47.2) 79 (44.1)
GG 9 (7.7) 20 (11.2) 12 (6.7)
1050G> T GG 34 (29.8) 53 (29.6) 59 (33.3) NS NS NS
GT 63 (55.3) 97 (54.2) 93 (52.5)
TT 17 (14.9) 29 (16.2) 25 (14.1)
564C> T CC 60 (51.3) 85 (48.3) 91 (50. 6) NS NS NS
CT 49 (41.9) 74 (42.1) 71 (39.4)
TT 8 (6.8) 17 (9.7) 18 (10.0)
A299A CC 71 (59.7) 106 (59. 9) 106 (58. 9) NS NS NS
CT 45 (37.8) 63 (35.6) 62 (34.4)
TT 3 (2.5) 8 (4.5) 12 (6. 7)
AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; NC, normal control; NS, not significant.
*P value in dominant model with OR (95% confidence interval) of 0.52 (0.30e0.87);. yP value in recessive model with OR (95% confidence
interval) of 3.22 (1.50e6.92).
360 S.-H. Kim et al.The molecular mechanisms explaining how a variant in
the 30-UTR could induce changes in bronchial responses to
aspirin remain to be explained. However, one possibility is
that the nucleotide change induced stability of the mRNA
transcript and increased gene expression, thus influencing
the development of phenotypes.34 Our positive association
of the 30-UTR SNP with AIA is coincident with the finding
that three polymorphisms in the 30-UTR of ADORA1 were
associated with specific infarct changes in ischemic
cardiomyopathy mediated through mRNA structural differ-
ences.35 Based on these findings, we speculated that aspirinchanged the levels of adenosine in the airways of individ-
uals with asthma and the different effects observed with
aspirin between normal subjects and patients with AIA was
due to altered expression of the adenosine receptor A1.
Currently, we do not know whether adenosine receptor
expression in AIA is different from that in ATA. Further
studies are needed to clarify this issue and the role of
adenosine receptors in AIA.
The adenosine A2A receptor is expressed on inflamma-
tory cells and mediates inhibitory signals by increasing
intracellular cAMP upon activation. Stimulation of A2A
Table 4 Haplotype frequencies in patients with AIA, ATA, and control subjects.
Gene Haplotype* AIA (nZ 136) ATA (nZ 181) NC (nZ 183) P value
AIA vs. ATA AIA vs. NC ATA vs. NC
ADORA1 ht1[CeCeG] 0.375 0.366 0.400 NS NS NS
ht2[CeTeG] 0.375 0.300 0.283 NS 0.003y NS
ht3[AeCeG] 0.134 0.203 0.164 0.032z NS NS
ht4[CeCeT] 0.112 0.131 0.153 NS NS NS
ADORA2A ht1[AeC] 0.567 0.554 0.526 NS NS NS
ht2[AeT] 0.255 0.323 0.349 NS 0.013x NS
ht3[CeT] 0.174 0.123 0.122 NS NS NS
ADORA3 ht1[CeCeTeG] 0.319 0.341 0.294 NS NS NS
ht2[CeCeGeA] 0.305 0.267 0.294 NS NS NS
ht3[TeTeGeA] 0.217 0.216 0.221 NS NS NS
ht4[CeCeTeA] 0.102 0.085 0.109 NS NS NS
ht5[CeTeGeA] 0.058 0.085 0.071 NS NS NS
AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; NC, normal control; NS, not significant.
*Haplotypes with frequencies >0.05 are listed in descending order; ADORA1 haplotype of [1278C> A_1405C> T_1627G> T], ADORA2A
haplotype of [1751A> C_Y361Y], and ADORA3 haplotype of [-2288A> G_1050G> T_564C> T_A299A]; yP value in recessive model
with OR (95% confidence interval) of 3.04 (1.42e6.50); zP value in dominant model with OR (95% confidence interval) of 0.56 (0.33e0.95);
xP value in recessive model with OR (95% confidence interval) of 0.33 (0.13e0.82).
Adenosine deaminase and adenosine receptor polymorphisms 361receptor is linked to inhibition of degranulation in neutro-
phils,36 eosinophils, and mast cells.37 Additionally, an A2A
receptor agonist attenuated airway inflammation in an
allergen-induced animal model of asthma38 and A2A
receptor-deficient mice exhibited enhanced AHR and
airway inflammation.39 In contrast to negative results in
single SNP analysis, the haplotype examination of the A2A
receptor gene was significantly associated with the AIA
phenotype with ht2[AeT], encompassing 1751A> C in the
promoter region and Y361Y in exon 2. Although we are not
able to explain any functional role of this haplotype in theCC+CT TT
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Figure 1 Time for maximal airway obstruction in the aspirin
inhalation provocation test according to genotypes in
1405C> T. More prompt bronchospasm after aspirin inhalation
in patients with TT homozygotes compared to those with CC or
CT among patients with AIA.pathogenesis of AIA, we speculated that levels of gene
expression might change with different promoter poly-
morphisms. The altered expression of A2A receptors in
patients with asthma could explain the different inflam-
matory responses to aspirin administration.
In contrast to the anti-inflammatory effects of the A2A
receptor, the A2B receptor expressed on mast cells and
airway smooth muscle cells has pro-inflammatory effects by
way of released inflammatory mediators and cytokines. A
selective antagonist of the A2B receptor showed thera-
peutic effects in a mouse model of asthma by attenuating
bronchoconstriction and inflammation.40 Based on these
findings, the adenosine A2B receptor is now an important
therapeutic target in asthma. With regard to genetic vari-
ations in the A2B receptor, previous studies reported that
allelic frequency differed according to ethnicity and that
no common SNP occurred in all ethnic populations.41
Consistent with this finding, we did not identify any genetic
variation greater than 5%, and therefore conducted no
further genotyping of our study population.
While the A3 receptor expression was elevated on
eosinophils in patients with asthma,42 the role of A3
receptors in the airways is somewhat contradictory. Earlier
studies reported that A3 receptor stimulation induced
inhibition of eosinophil degranulation and migration.43
Contrary to this result, inhibition of A3 receptors with
a selective antagonist in ADA-deficient mice attenuated
eosinophilic lung inflammation.44 Although these findings
suggest that adenosine acts on pulmonary inflammation via
the A3 receptor, no significant association was detected
between genetic polymorphisms in A3 receptors and aspirin
tolerance in asthma.
While more severe eosinophilic inflammation was
observed in the airways of subjects with AIA, whether
differences of either adenosine concentrations or metabo-
lism exist between individuals with AIA and ATA remains
unclear. Among enzymes involved in adenosine metabolism,
362 S.-H. Kim et al.we targeted ADA because it is the primary catabolic
enzyme for adenosine and ADA-deficient mice exhibited
a marked elevation of adenosine and early death
accompanied by asthmatic phenotypes, including eosino-
philic lung inflammation, mucus production, and elevation
of Th2 cytokines.11 Additionally, significant effects of ADA
polymorphisms in atopy and asthma have been repor-
ted.18 However, we could not find an association between
ADA polymorphisms and AIA development in this study.
In summary, the present study revealed that genetic
polymorphisms of ADORA1 and ADORA2A were significantly
associated with AIA in a Korean population. These findings
suggest that adenosine might play a crucial role in the
development of AIA by mediation of A1 and A2A receptors.
Further studies will be necessary to elucidate the func-
tional mechanisms of these genetic variations and to
determine their presence in other ethnic populations.
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